Ocuphire Pharma, Inc.(OCUP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OCUP Ocuphire Pharma, Inc.

Post-Mkt 01-16 16:01:44 EST

1.17

+0.00

0.00%

High1.17	Low1.17	Vol0.00
Open1.17	D1 Closing1.17	Amplitude0.00%
Mkt Cap30.65M	Tradable Cap28.69M	Total Shares26.20M
T/O792.87K	T/O Rate0.00%	Tradable Shares24.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OCUP","market":"US","secType":"STK","nameCN":"Ocuphire Pharma, Inc.","latestPrice":1.17,"timestamp":1729713600000,"preClose":1.17,"halted":8,"volume":0,"delay":0,"floatShares":24519364,"shares":26198444,"eps":-0.595078,"marketStatus":"Post-Mkt","change":0,"latestTime":"01-16 16:01:44 EST","open":1.17,"high":1.17,"low":1.17,"amount":792873.8741365001,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.595078,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768611600000},"marketStatusCode":4,"symbolChange":{"newSymbol":"IRD","executeDate":"2024-10-24"},"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":1.17,"volumeRatio":0},"requestUrl":"/m/hq/s/OCUP/wiki","defaultTab":"wiki","newsList":[{"id":"2478956590","title":"Ocuphire Pharma Acquires Opus Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2478956590","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478956590?lang=en_us&edition=fundamental","pubTime":"2024-10-26 00:19","pubTimestamp":1729873179,"startTime":"0","endTime":"0","summary":"Ocuphire Pharma  acquired Opus Genetics and the combined company will operate as Opus Genetics, the Retinal Degeneration Fund said Friday.The combined company will focus on developing gene therapies to cure genetic eye disorders and trade on the Nasdaq under the ticker \"IRD\", the RD Fund added.Financial terms of the transaction were not disclosed.Ocuphire Pharma shares were down 12% in recent trading.Price: 1.17, Change: -0.16, Percent Change: -12.03","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCUP","BK4007"],"gpt_icon":0},{"id":"2477578935","title":"Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2477578935","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477578935?lang=en_us&edition=fundamental","pubTime":"2024-10-24 02:07","pubTimestamp":1729706820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OCUP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 23, 2024 14:07 ET (18:07 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUP"],"gpt_icon":0},{"id":"2477399954","title":"BRIEF-Ocuphire Pharma announces acquisition of Opus Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2477399954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477399954?lang=en_us&edition=fundamental","pubTime":"2024-10-23 05:16","pubTimestamp":1729631797,"startTime":"0","endTime":"0","summary":"Oct 22  - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES ACQUISITION OF OPUS GENETICS   * OCUPHIRE PHARMA INC - PROJECTED CASH RUNWAY EXTENDED INTO 2026   * OCUPHIRE PHARMA INC - COMBINED COMPANY TO BE RENAMED OPUS GENETICS, TRADING AS 'IRD'   * OCUPHIRE PHARMA INC - GEORGE MAGRATH TO CONTINUE AS CEO OF COMBINED COMPANY   * OCUPHIRE PHARMA INC - STOCKHOLDERS TO OWN 58%, OPUS GENETICS STOCKHOLDERS 42% OF COMBINED CO   * OCUPHIRE PHARMA INC - LYNX-2 PHASE 3 TRIAL ON TRACK FOR TOP-LINE DATA IN Q1 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUP","BK4007"],"gpt_icon":1},{"id":"2477974360","title":"Ocuphire Pharma Announces Acquisition of Opus Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2477974360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477974360?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA8PRKPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OCUP"],"gpt_icon":0},{"id":"2477484360","title":"Ocuphire Pharma Inc - Stockholders to Own 58%, Opus Genetics Stockholders 42% of Combined Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2477484360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477484360?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA8PRKPS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OCUP"],"gpt_icon":0},{"id":"2477436017","title":"Ocuphire Pharma Inc - Combined Company to Be Renamed Opus Genetics, Trading as 'Ird'","url":"https://stock-news.laohu8.com/highlight/detail?id=2477436017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477436017?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA8PRKPS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCUP","BK4007"],"gpt_icon":0},{"id":"2477431360","title":"Ocuphire Pharma Inc - Lynx-2 Phase 3 Trial on Track for Top-Line Data in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2477431360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477431360?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA8PRKPS:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OCUP"],"gpt_icon":0},{"id":"2477360480","title":"Ocuphire Pharma Inc - George Magrath to Continue as CEO of Combined Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2477360480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477360480?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA8PRKPS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCUP","BK4007"],"gpt_icon":0},{"id":"2477360172","title":"Ocuphire Pharma Inc - Projected Cash Runway Extended Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2477360172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477360172?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:05","pubTimestamp":1729627501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA8PRKPS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCUP","BK4007"],"gpt_icon":0},{"id":"2471880470","title":"BRIEF-Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2471880470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471880470?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:27","pubTimestamp":1727699255,"startTime":"0","endTime":"0","summary":"Sept 30  - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES PUBLICATION OF FULL PHASE 3 RESULTS OF PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PHARMACOLOGICALLY-INDUCED MYDRIASIS IN OPHTHALMOLOGY   * OCUPHIRE PHARMA INC: PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% EXHIBITED A FAVORABLE SAFETY PROFILE   * OCUPHIRE PHARMA INC:  VEGA-3 PHASE 3 CLINICAL TRIAL TOP-LINE DATA ARE EXPECTED IN FIRST HALF OF 2025   * OCUPHIRE PHARMA INC:  LYNX-2 PHASE 3 TRIAL TOP-LINE DATA ARE EXPECTED IN Q1 OF 2025.Source text for Eikon:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUP","BK4007"],"gpt_icon":0},{"id":"2471809074","title":"Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology","url":"https://stock-news.laohu8.com/highlight/detail?id=2471809074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471809074?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:00","pubTimestamp":1727697643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3LC0VU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCUP","BK4007"],"gpt_icon":0},{"id":"2471809047","title":"Ocuphire Pharma Inc: Phentolamine Ophthalmic Solution 0.75% Exhibited a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2471809047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471809047?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:00","pubTimestamp":1727697643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3LC0VU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCUP","BK4007"],"gpt_icon":0},{"id":"2471780130","title":"Ocuphire Pharma Inc:  Vega-3 Phase 3 Clinical Trial Top-Line Data Are Expected in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2471780130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471780130?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:00","pubTimestamp":1727697643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3LC0VU:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OCUP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocuphire.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.45,"avgChangeRate":0.081272},{"month":2,"riseRate":0.5,"avgChangeRate":0.063536},{"month":3,"riseRate":0.35,"avgChangeRate":0.008391},{"month":4,"riseRate":0.421053,"avgChangeRate":0.546155},{"month":5,"riseRate":0.6,"avgChangeRate":4.57464},{"month":6,"riseRate":0.4,"avgChangeRate":-0.017062},{"month":7,"riseRate":0.35,"avgChangeRate":-0.003257},{"month":8,"riseRate":0.35,"avgChangeRate":-0.024514},{"month":9,"riseRate":0.45,"avgChangeRate":-0.02299},{"month":10,"riseRate":0.25,"avgChangeRate":-0.107241},{"month":11,"riseRate":0.315789,"avgChangeRate":-0.064728},{"month":12,"riseRate":0.45,"avgChangeRate":0.058972}],"exchange":"NASDAQ","name":"Ocuphire Pharma, Inc.","nameEN":"Ocuphire Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ocuphire Pharma, Inc.(OCUP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ocuphire Pharma, Inc.(OCUP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ocuphire Pharma, Inc.,OCUP,Ocuphire Pharma, Inc.股票,Ocuphire Pharma, Inc.股票老虎,Ocuphire Pharma, Inc.股票老虎国际,Ocuphire Pharma, Inc.行情,Ocuphire Pharma, Inc.股票行情,Ocuphire Pharma, Inc.股价,Ocuphire Pharma, Inc.股市,Ocuphire Pharma, Inc.股票价格,Ocuphire Pharma, Inc.股票交易,Ocuphire Pharma, Inc.股票购买,Ocuphire Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ocuphire Pharma, Inc.(OCUP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ocuphire Pharma, Inc.(OCUP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction